This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Ellipses Pharma Limited, Institute of Cancer Research: Royal Cancer Hospital (the). Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 6 
1 out of 13 Years Active: 2026
Title: Gavin Halbert and His Pharmaceutical Patent
Introduction
Gavin Halbert is an inventor associated with Glasgow, Great Britain. His patent work concerns pharmaceutical compounds investigated for their potential relevance to cancer and other diseases.
Latest Patents
Halbert is associated with 1 patent: “Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine.” The invention describes salts and polymorphic forms of Compound A, a compound that inhibits Aurora kinase and FMS-like tyrosine kinase 3 (FLT3) activity. It also covers methods for preparing these forms, pharmaceutical compositions containing them, and their potential use in treating proliferative disorders such as cancer, along with other conditions in which Aurora kinase or FLT3 activity is implicated.
Career Highlights
Halbert’s listed professional affiliations include the Institute of Cancer Research: Royal Cancer Hospital and Ellipses Pharma Limited. His patent reflects work on the preparation and pharmaceutical application of a compound targeting kinase activity.
Collaborations
Named coworkers associated with Halbert include Natalie Kelk and Jonathan Loughrey.
Conclusion
Gavin Halbert’s recorded patent activity centers on pharmaceutical forms of a kinase-inhibiting compound and their potential therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile